Complete Filing Data
Silence Therapeutics plc reported Goodwill of $10.62 million for FY2025.
All values from 10-K, 20-F, and 10-Q filings on SEC EDGAR, organized by financial statement. Scroll each table horizontally for the full history. Blank cells mean Silence Therapeutics plc did not report that metric for that period in XBRL — often because accounting standards changed which tag a company files under (for example, most companies moved revenue to the ASC-606 tag in 2018), so a metric may continue in a different row. Rows marked * merge those successor tags into one continuous series, preferring the audited value from the newest-standard tag where periods overlap.
Income Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Net Income * | -$88.6M | -$45.3M | -$54.2M | -$50.3M | -$39.4M | -$32.5M | -$19.6M |
| Research And Development Expense | $67.8M | $67.9M | $56.9M | $43.6M | $30.8M | $20.2M | $13.3M |
| Gross Profit | $344.0K | $31.4M | $18.8M | $8.2M | $5.0M | $1.7M | $244.0K |
| General And Administrative Expense | $22.3M | $26.9M | $26.2M | $25.7M | $20.0M | $14.0M | $9.6M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | $8.8M | -$1.1M | $789.0K | -$86.0K | |||
| Gain From Research And Development Credit | $7.5M | $13.7M | $11.9M | $9.8M | |||
| Revenue From Contract With Customer Excluding Assessed Tax | $559.0K | $43.3M | $31.6M | $21.7M | |||
| Other Nonoperating Income | $3.5M | $4.5M | $1.8M | $280.0K | |||
| Other Comprehensive Income Loss Net Of Tax | $8.8M | -$1.1M | $789.0K | -$86.0K | |||
| Operating Income Loss | -$91.1M | -$63.3M | -$64.4M | -$61.0M | |||
| Income Tax Expense Benefit | $11.0K | $845.0K | $956.0K | $688.0K | |||
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$88.6M | -$44.5M | -$53.3M | -$49.6M | |||
| Cost Of Goods And Services Sold | $215.0K | $11.8M | $12.9M | $13.5M | |||
| Comprehensive Income Net Of Tax | -$79.8M | -$46.4M | -$53.4M | -$50.4M | |||
| Profit Loss From Operating Activities | -$49.6M | -$48.6M | -$45.8M | -$35.8M | -$22.7M | ||
| Profit Loss Before Tax | -$50.3M | -$47.4M | -$45.9M | -$36.0M | -$22.9M | ||
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | -$134.0K | $544.0K | -$677.0K | $472.0K | -$411.0K | ||
| Other Comprehensive Income | -$134.0K | $544.0K | -$677.0K | $472.0K | -$411.0K | ||
| Income Tax Expense Continuing Operations | -$7.0M | -$6.9M | -$6.4M | -$3.5M | -$3.3M | ||
| Comprehensive Income | -$43.4M | -$39.9M | -$40.1M | -$32.1M | -$20.0M | ||
| Revenue From Contracts With Customers | $25.4M | $17.5M | $12.4M | $5.5M | $244.0K | ||
| Restructuring Charges | $1.3M | $0.00 | |||||
| Deferred Income Tax Expense Benefit | $11.0K | $845.0K | $956.0K | $688.0K | |||
| Adjustments For Research And Development Tax Credits Received | $6.9M | $7.8M | $4.4M | $3.0M | $2.3M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Net Income * | -$21.0M | -$27.4M | -$28.5M | -$35.5M | -$19.8M | -$2.3M |
| Research And Development Expense | $20.5M | $17.6M | $20.8M | $20.2M | $13.8M | $11.8M |
| Gross Profit | $95.0K | $139.0K | $88.0K | -$2.1M | -$2.6M | $12.9M |
| General And Administrative Expense | $5.8M | $5.1M | $7.7M | $7.7M | $7.0M | $6.6M |
| Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax | -$1.7M | $6.7M | $3.7M | $7.7M | $186.0K | -$57.0K |
| Gain From Research And Development Credit | $2.6M | $2.4M | $2.7M | $4.5M | $2.7M | $2.5M |
| Revenue From Contract With Customer Excluding Assessed Tax | $159.0K | $224.0K | $142.0K | $1.5M | $756.0K | $15.7M |
| Other Nonoperating Income | $770.0K | $861.0K | $969.0K | $1.4M | $1.4M | $667.0K |
| Other Comprehensive Income Loss Net Of Tax | -$1.7M | $6.7M | $3.7M | $7.7M | $186.0K | -$57.0K |
| Operating Income Loss | -$26.2M | -$24.0M | -$28.4M | -$30.0M | -$23.4M | -$5.6M |
| Income Tax Expense Benefit | $1.0K | $10.0K | $0.00 | $49.0K | $228.0K | $244.0K |
| Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest | -$21.0M | -$27.3M | -$28.5M | -$35.5M | -$19.5M | -$2.1M |
| Cost Of Goods And Services Sold | $64.0K | $85.0K | $54.0K | $3.6M | $3.3M | $2.8M |
| Comprehensive Income Net Of Tax | -$22.6M | -$20.7M | -$24.8M | -$27.9M | -$19.6M | -$2.4M |
| Profit Loss From Operating Activities | ||||||
| Profit Loss Before Tax | ||||||
| Other Comprehensive Income Net Of Tax Exchange Differences On Translation | ||||||
| Other Comprehensive Income | ||||||
| Income Tax Expense Continuing Operations | ||||||
| Comprehensive Income | ||||||
| Revenue From Contracts With Customers | ||||||
| Restructuring Charges | $0.00 | $1.3M | $0.00 | $0.00 | ||
| Deferred Income Tax Expense Benefit | $0.00 | $244.0K | ||||
| Adjustments For Research And Development Tax Credits Received |
Balance Sheet
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Goodwill | $10.6M | $9.4M | $10.0M | $9.7M | $7.6M | $8.1M | $7.7M | |
| Stockholders Equity | $62.3M | $134.0M | $22.0M | $27.2M | $12.4M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $11.3M | $121.3M | $68.8M | $66.3M | $99.4M | |||
| Cash And Cash Equivalents | $54.0M | $54.8M | $73.5M | $27.4M | $13.5M | $21.5M | ||
| Equity | $62.3M | $134.0M | $22.0M | $27.2M | $12.4M | |||
| Purchase Of Property Plant And Equipment Classified As Investing Activities | $45.0K | $140.0K | $1.3M | $511.0K | $9.0K | |||
| Issue Of Equity | $25.3M | $43.2M | $30.9M | $15.8M | $5.3M | |||
| Cash Flows From Used In Operations | -$45.6M | -$45.5M | $2.4M | -$13.8M | -$581.0K | |||
| Cash Flows From Used In Operating Activities | -$39.4M | -$45.5M | $6.8M | -$10.8M | $1.7M | |||
| Cash Flows From Used In Investing Activities | $16.4M | -$16.5M | $8.7M | $9.6M | -$15.0M | |||
| Cash Flows From Used In Financing Activities | $25.2M | $43.0M | $30.7M | $15.4M | $5.3M | |||
| Adjustments For Increase Decrease In Trade And Other Payables | $44.0K | $1.4M | $2.4M | $1.3M | $3.1M | |||
| Adjustments For Decrease Increase In Trade And Other Receivables | $314.0K | -$584.0K | $27.5M | -$29.3M | -$4.0K | |||
| Adjustments For Decrease Increase In Other Current Assets | $610.0K | -$4.2M | -$904.0K | -$3.7M | -$4.0K | |||
| Current Tax Assets Current | $17.6M | $14.9M | $6.9M | $3.5M | $3.1M | |||
| Common Stock Value | $10.3M | $10.3M | $8.8M | $8.2M | ||||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$110.2M | $52.5M | $1.8M | -$25.0M | ||||
| Adjustments For Decrease Increase In Contract Liabilities | -$8.3M | -$4.4M | $8.4M | $50.4M | $18.0M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Goodwill | $10.6M | $10.6M | $9.8M | $9.4M | $9.8M | |
| Stockholders Equity | $74.1M | $94.2M | $112.7M | $126.7M | $142.5M | $156.8M |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations | $82.0M | $41.7M | $64.9M | $82.9M | $138.5M | $142.7M |
| Cash And Cash Equivalents | ||||||
| Equity | $74.1M | $94.2M | $112.7M | $126.7M | $142.5M | $156.8M |
| Purchase Of Property Plant And Equipment Classified As Investing Activities | ||||||
| Issue Of Equity | ||||||
| Cash Flows From Used In Operations | ||||||
| Cash Flows From Used In Operating Activities | ||||||
| Cash Flows From Used In Investing Activities | ||||||
| Cash Flows From Used In Financing Activities | ||||||
| Adjustments For Increase Decrease In Trade And Other Payables | ||||||
| Adjustments For Decrease Increase In Trade And Other Receivables | ||||||
| Adjustments For Decrease Increase In Other Current Assets | ||||||
| Current Tax Assets Current | ||||||
| Common Stock Value | $10.3M | $10.3M | $10.3M | |||
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect | -$56.7M | $74.0M | ||||
| Adjustments For Decrease Increase In Contract Liabilities |
Cash Flow Statement
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Proceeds From Issuing Shares | 25.3M | 43.2M | 30.9M | 15.8M | 5.3M | ||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | -$3.0M | $228.0K | -$105.0K | -$336.0K | $36.0K | ||
| Share Based Compensation | $8.1M | $16.3M | $16.3M | $12.7M | |||
| Proceeds From Issuance Of Common Stock | $15.0K | $142.1M | $31.9M | $52.6M | |||
| Payments To Acquire Property Plant And Equipment | $55.0K | $211.0K | $56.0K | $173.0K | |||
| Net Cash Provided By Used In Operating Activities | -$62.3M | -$67.6M | -$49.5M | -$57.0M | |||
| Net Cash Provided By Used In Investing Activities | -$48.0M | -$22.0M | $19.3M | -$20.5M | |||
| Net Cash Provided By Used In Financing Activities | $15.0K | $142.1M | $31.9M | $52.6M | |||
| Increase Decrease In Trade And Other Payables | -$4.1M | $499.0K | -$473.0K | $2.0M | |||
| Increase Decrease In Research And Development Benefit Receivable | -$4.0M | $2.3M | $3.4M | $9.8M | |||
| Increase Decrease In Other Current Assets | -$6.0M | $1.3M | -$2.0M | $5.2M | |||
| Increase Decrease In Operating Lease Liability | -$168.0K | -$165.0K | -$175.0K | -$235.0K | |||
| Increase Decrease In Contract With Customer Liability | -$334.0K | -$28.8M | -$10.3M | -$5.4M | |||
| Increase Decrease In Accounts Receivable | -$1.0M | $904.0K | -$392.0K | $723.0K | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $195.0K | $60.0K | $749.0K | -$8.1M |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q1 2025 | Q1 2024 |
|---|---|---|
| Proceeds From Issuing Shares | ||
| Effect Of Exchange Rate Changes On Cash And Cash Equivalents | ||
| Share Based Compensation | $3.5M | $4.1M |
| Proceeds From Issuance Of Common Stock | $14.0K | $133.0M |
| Payments To Acquire Property Plant And Equipment | $4.0K | $0.00 |
| Net Cash Provided By Used In Operating Activities | -$12.3M | -$9.1M |
| Net Cash Provided By Used In Investing Activities | -$44.4M | -$49.9M |
| Net Cash Provided By Used In Financing Activities | $14.0K | $133.0M |
| Increase Decrease In Trade And Other Payables | $1.8M | -$2.8M |
| Increase Decrease In Research And Development Benefit Receivable | -$8.3M | -$8.8M |
| Increase Decrease In Other Current Assets | $592.0K | $768.0K |
| Increase Decrease In Operating Lease Liability | -$59.0K | $16.0K |
| Increase Decrease In Contract With Customer Liability | -$72.0K | -$5.5M |
| Increase Decrease In Accounts Receivable | -$940.0K | $10.0M |
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | $232.0K | -$35.0K |
Per-Share & Share Counts
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 141.7M | 138.8M | 111.3M | 96.6M |
| Weighted Average Number Of Diluted Shares Outstanding | 141.7M | 138.8M | 111.3M | 96.6M |
| Earnings Per Share Diluted | $-0.63 | $-0.33 | $-0.49 | $-0.52 |
| Earnings Per Share Basic | $-0.63 | $-0.33 | $-0.49 | $-0.52 |
| Common Stock Par Or Stated Value Per Share | $0.05 | $0.05 | $0.05 | $0.05 |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Weighted Average Number Of Shares Outstanding Basic | 141.7M | 141.7M | 141.7M | 141.2M | 140.2M | 131.9M |
| Weighted Average Number Of Diluted Shares Outstanding | 141.7M | 141.7M | 141.7M | 141.2M | 140.2M | 131.9M |
| Earnings Per Share Diluted | $-0.15 | $-0.19 | $-0.20 | $-0.25 | $-0.14 | $-0.02 |
| Earnings Per Share Basic | $-0.15 | $-0.19 | $-0.20 | $-0.25 | $-0.14 | $-0.02 |
| Common Stock Par Or Stated Value Per Share | $0.05 | $0.05 | $0.05 |
Other Metrics
Annual (10-K / 20-F)
| Metric \ Fiscal Year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $8.1M | $16.3M | $16.3M | $12.7M | |||
| Stock Issued During Period Value New Issues | $15.0K | $142.1M | $31.9M | $52.6M | |||
| Foreign Currency Transaction Gain Loss Before Tax | -$8.5M | $646.0K | -$2.6M | $1.3M | |||
| Issued Capital | $5.9M | $5.4M | $4.5M | $4.2M | $3.9M | ||
| Interest Received Paid Classified As Investing Activities | $958.0K | $23.0K | $10.0K | $129.0K | -$6.0K | ||
| Increase Decrease Through Sharebased Payment Transactions | $13.1M | $10.3M | $8.6M | $4.4M | $584.0K | ||
| Increase Decrease Through Other Contributions By Owners | $38.4M | $53.5M | $39.6M | $20.2M | $5.9M | ||
| Finance Income | $1.4M | $1.3M | $10.0K | $129.0K | $27.0K | ||
| Adjustments For Sharebased Payments | $13.1M | $10.3M | $8.6M | $4.4M | $584.0K | ||
| Adjustments For Finance Income | $1.4M | $1.3M | $10.0K | $128.0K | $27.0K | ||
| Adjustments For Depreciation Expense | $462.0K | $478.0K | $411.0K | $476.0K | $452.0K | ||
| Adjustments For Amortisation Expense | $36.0K | $4.0K | $16.0K | $20.0K | $30.0K | ||
| Purchase Of Term Deposits | $166.4M | $139.2M | $25.8M | $20.0M | |||
| Other Income | $3.5M | $4.5M | $1.8M | $280.0K | |||
| Net Foreign Exchange Impacts | -$11.0M | $2.6M | -$4.0M | $1.0M | |||
| Finance Costs | $2.2M | $47.0K | $52.0K | $323.0K | $163.0K | ||
| Depreciation | $312.0K | $336.0K | $369.0K | $379.0K |
Quarterly (10-Q, single quarters)
| Metric \ Quarter | Q3 2025 | Q2 2025 | Q1 2025 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|---|---|
| Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value | $2.5M | $2.1M | $3.5M | $4.1M | $4.1M | $4.1M |
| Stock Issued During Period Value New Issues | $1.0K | $14.0K | $8.0M | $1.2M | $133.0M | |
| Foreign Currency Transaction Gain Loss Before Tax | $1.9M | -$6.6M | -$3.8M | -$11.4M | -$222.0K | $351.0K |
| Issued Capital | ||||||
| Interest Received Paid Classified As Investing Activities | ||||||
| Increase Decrease Through Sharebased Payment Transactions | ||||||
| Increase Decrease Through Other Contributions By Owners | ||||||
| Finance Income | ||||||
| Adjustments For Sharebased Payments | ||||||
| Adjustments For Finance Income | ||||||
| Adjustments For Depreciation Expense | ||||||
| Adjustments For Amortisation Expense | ||||||
| Purchase Of Term Deposits | $70.1M | $49.9M | ||||
| Other Income | $969.0K | $667.0K | ||||
| Net Foreign Exchange Impacts | -$3.0M | $355.0K | ||||
| Finance Costs | ||||||
| Depreciation | $73.0K | $88.0K |
Most recent annual filing with the SEC: March 5, 2026
Data sourced from SEC EDGAR public filings as of August 5, 2026.